Stock Events

Stock Events

NurExone Biologic 

€0.4
17
-€0.03-6.74% Today

Statistics

Day High
0.4
Day Low
0.4
52W High
0.7
52W Low
0.35
Volume
-
Avg. Volume
-
Mkt Cap
33.07M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3JunExpected
Q3 2024
Q1 2025
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.03
-0.01
0
0.02
Expected EPS
-0.0173746
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-9.58MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow J90.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap25.38B
Biogen focuses on neurodegenerative diseases, directly competing with NurExone's focus on neurological recovery.
Ionis Pharmaceuticals
IONS
Mkt Cap12.42B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery, overlapping with NurExone's RNA-based therapies.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.72B
Alnylam Pharmaceuticals works on RNA interference (RNAi) therapeutics, competing in the RNA-based treatment space.
Sarepta Therapeutics
SRPT
Mkt Cap2.22B
Sarepta Therapeutics focuses on genetic modulation therapies, including RNA-based treatments, competing in similar therapeutic areas.
Vertex Pharmaceuticals
VRTX
Mkt Cap110.97B
Vertex Pharmaceuticals engages in creating new therapies for genetic diseases, potentially overlapping with NurExone's target indications.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.17B
Regeneron Pharmaceuticals is involved in neurology and other areas, competing for similar patient populations.
Novartis
NVS
Mkt Cap297.35B
Novartis offers a broad range of neurology treatments, directly competing in NurExone's market.
Pfizer
PFE
Mkt Cap153.13B
Pfizer has a diverse portfolio that includes treatments for neurological conditions, competing for similar therapeutic areas.
Rogers
ROG
Mkt Cap2.1B
Roche, with its strong focus on neuroscience and RNA-based therapies, competes in similar research and development areas.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.49B
BioMarin Pharmaceutical focuses on genetic diseases, some of which overlap with NurExone's therapeutic targets.

About

NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis caused by spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat traumatic brain injuries and other neurological conditions. Its technology includes ExoPTEN for the treatment of acute spinal cord injury and glaucoma; and Exosomes as a drug delivery system for regeneration and healing of specific tissues. The company was founded in 2020 and is based in Toronto, Canada.
Show more...
CEO
Mr. Yoram Drucker
Country
Germany
ISIN
CA67059R1091
WKN
000A3DNSU

Listings

STU
DE
J90.STU
MU
DE
J90.MU
F
DE
J90.F
V
CA
NRX.V

0 Comments

Share your thoughts

FAQ

What is NurExone Biologic stock price today?▼
The current price of J90.F is €0.4 EUR — it has decreased by -6.74% in the past 24 hours. Watch NurExone Biologic stock price performance more closely on the chart.
What is NurExone Biologic stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange NurExone Biologic stocks are traded under the ticker J90.F.
Is NurExone Biologic stock price growing?▼
J90.F stock has risen by +11.39% compared to the previous week, the month change is a +3.08% rise, over the last year NurExone Biologic has showed a -8.86% decrease.
What is NurExone Biologic market cap?▼
Today NurExone Biologic has the market capitalization of 33.07M
When is the next NurExone Biologic earnings date?▼
NurExone Biologic is going to release the next earnings report on June 03, 2026.
What is NurExone Biologic revenue for the last year?▼
NurExone Biologic revenue for the last year amounts to 0 EUR.
What is NurExone Biologic net income for the last year?▼
J90.F net income for the last year is -9.58M EUR.
In which sector is NurExone Biologic located?▼
NurExone Biologic operates in the Health & Wellness sector.
When did NurExone Biologic complete a stock split?▼
The last stock split for NurExone Biologic was on June 22, 2022 with a ratio of 1:10.
Where is NurExone Biologic headquartered?▼
NurExone Biologic is headquartered in Toronto, Germany.